Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
382 hedge funds and large institutions have $2.59B invested in Catalyst Pharmaceutical in 2026 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 147 increasing their positions, 120 reducing their positions, and 40 closing their positions.
43% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 40
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
23% more repeat investments, than reductions
Existing positions increased: 147 | Existing positions reduced: 120
7% more capital invested
Capital invested by funds: $2.42B → $2.59B (+$165M)
2% more funds holding
Funds holding: 374 → 382 (+8)
1.11% more ownership
Funds ownership: 84.57% → 85.68% (+1.1%)
31% less call options, than puts
Call options by funds: $3.38M | Put options by funds: $4.88M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$26.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$19.9M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.4M |
| 4 |
CCMG
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
+$13.5M |
| 5 |
IMC Chicago
Chicago,
Illinois
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fundsmith LLP
London,
United Kingdom
|
-$60M |
| 2 |
DM
Deerfield Management
New York
|
-$23.1M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$15.8M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$12.9M |
| 5 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$12.6M |
CPRX Hedge Fund Activity: Q1 2026 in Review
382 of the 8,190 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2026, worth a combined $2.59B — up 6.8% from $2.42B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new CPRX positions and 40 closed out — a net gain of 17 holders — while 147 added to existing stakes and 120 trimmed.
The largest buyer was American Century Companies, adding an estimated $26.5M. The largest seller was Fundsmith LLP, cutting an estimated $60M.
- 382 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2026, up from 374 in Q4 2025.
- Funds reported $2.59B of Catalyst Pharmaceutical stock for Q1 2026, up 6.8% quarter-over-quarter.
- 57 funds opened new Catalyst Pharmaceutical positions in Q1 2026 and 40 closed out, a net change of +17 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2026 was American Century Companies, an estimated $26.5M added.
- The largest Catalyst Pharmaceutical seller in Q1 2026 was Fundsmith LLP, an estimated $60M sold.
Based on aggregated 13F filings for Q1 2026.